Skip to content
20 November · 06:30 UTCFollow GSK by emailFollow

GSK · Pharma and healthcare · one day

GSK (GSK): news on Friday 20 November 2026

News from the 24 hours to Friday morning, 20 November 2026.

Tone of the day

+6.3strongly positive
Relevant headlines22of 25 read
Stories6grouped by event

What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Why it scored this way

Coverage mainly covered a second US approval for a lung cancer drug from the Nuvalent purchase and Japanese orphan drug status for velzatinib in GIST. Antibiotic manufacturing certification added to the positive tone, though one report noted a share price fall of 1.7%.

What drove it

  • FDA lung cancer approval
  • velzatinib orphan designation
  • antibiotic manufacturing certification

Around this day

DayToneHeadlines
Sat 14 Nov+9.220
Sun 15 Nov+7.06
Mon 16 Nov+2.54
Tue 17 Nov+5.78
Wed 18 Nov+7.536
Thu 19 Nov0.01
Fri 20 Nov+6.322

6 stories · 22 headlines · strongest first

Pharma and healthcare on 20 NovemberFTSE 100 that day
ToneWhat the article reported, and why it scored that waySource
Japan gives velzatinib orphan designation for GIST +5.88 headlines today · Japan has given GSK's velzatinib orphan drug status for gastrointestinal stromal tumours, and pivotal data are expected in 2027.
+6.3Designation plus a stated timeline for key trial data.Proactive Investors UK (opens the article) ↗
+5.8Company's own announcement of Japanese orphan status.TradingView (opens the article) ↗
+5.8Japanese special status for a cancer drug candidate aids development.Moomoo (opens the article) ↗
+5.8Rare-tumour drug receives favourable Japanese designation.Kalkine Media (opens the article) ↗
+5.7Orphan status in Japan supports the GIST candidate.MarketScreener (opens the article) ↗
+5.7Japanese orphan status granted for GIST treatment.TradingView (opens the article) ↗
+5.7Japanese orphan designation for gastrointestinal tumour drug.TipRanks (opens the article) ↗
+5.5Late-stage drug obtains rare-disease status in Japan.Stock Titan (opens the article) ↗
Nelkarmi receives US accelerated approval for ALK-positive lung cancer +9.44 headlines today · 26 in all, since 18 November · Commentary on the FDA lung cancer approval and its Nuvalent-derived origin and implications for the oncology pipeline.
+10.0Second US regulatory clearance for a lung cancer therapy gained through acquisition.Zenopa (opens the article) ↗
+10.0Acquired company's drug gains another approval, validating the large purchase.pharma.economictimes.indiatimes.com (opens the article) ↗
+8.3Lung cancer approval strengthens oncology pipeline and savings outlook.Kalkine Media (opens the article) ↗
+7.5Investor-focused look at benefits of the new approval.Yahoo Finance (opens the article) ↗
GSK share outlook and market commentary 0.04 headlines today · 11 in all, since 17 November · Technical analysis and market pieces discuss GSK's share price moves and setup.
−4.2Share price fell during the session.Traders Union (opens the article) ↗
+0.8Generic market positioning commentary ahead of next trading day.Kalkine Media (opens the article) ↗
−0.8Technical chart note describing sideways trading near support.Traders Union (opens the article) ↗
+0.3Minor share price observation, essentially flat.AD HOC NEWS (opens the article) ↗
GSK wins UPC injunction against Pfizer and BioNTech +6.03 headlines today · 13 in all, since 12 November · Articles looking at what lies ahead for BioNTech refer to a window of three months tied to GSK, and to an FDA voucher.
+0.8Focuses on BioNTech's timeline, with GSK as a named counterparty.AD HOC NEWS (opens the article) ↗
+0.5BioNTech-focused timeline mentioning GSK window.AD HOC NEWS (opens the article) ↗
+0.5BioNTech-centred piece, GSK only a named party with a deadline.AD HOC NEWS (opens the article) ↗
GSK has its antibiotic production plants certified to the AMR standard +6.82 headlines today · GSK reported that all its antibiotic manufacturing sites are certified against an antimicrobial resistance standard.
+7.0All antibiotic plants meet an anti-resistance standard, helping reputation.Manufacturing Chemist (opens the article) ↗
+6.7Global certification for antibiotic production sites reflects well on GSK.Wisevoter (opens the article) ↗
ViiV Healthcare appoints HR business leader +0.71 headline today · 2 in all, since 15 November · Magnus Hibbert was promoted to a senior vice president HR role at GSK.
+0.8Routine senior HR appointment, little bearing on prospects.HR Today (opens the article) ↗

Each article has its own score. The lines are our own summary; follow the source link to read the article itself.

Follow by email

A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 20 November · 852 headlines · 87 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt